— Research note —
TB-500
Synthetic analog of thymosin beta-4 investigated for actin sequestration, angiogenesis, and tissue repair in preclinical research models.
TB-500 is a synthetic peptide marketed in research catalogs as a research analog corresponding to a fragment of the 43-amino-acid protein thymosin beta-4 (Tbeta4), one of the most abundant intracellular proteins in mammalian cells. Thymosin beta-4 was originally isolated from bovine thymus tissue by Goldstein and colleagues in the 1960s and 1970s, and was subsequently identified as a principal G-actin sequestering protein, regulating the monomeric actin pool available for filament assembly. The full-length recombinant Tbeta4 has been investigated in clinical research programs for corneal repair, dermal wound healing, and cardiac remodeling.
The TB-500 designation in the research-chemical market typically refers to a synthetic peptide containing the actin-binding domain (LKKTETQ region, residues 17-23) and surrounding sequence, though commercial preparations vary in exact composition. The shorter synthetic peptide has been promoted as a more cost-effective tool than full-length recombinant Tbeta4 for laboratory research on tissue repair, though the equivalence of biological activity between truncated synthetic peptide and full-length recombinant protein is debated in the literature.
Research interest in the thymosin beta-4 system spans angiogenesis, where the protein upregulates VEGF and promotes endothelial cell migration; cardiac repair, where studies in murine myocardial infarction models have reported preservation of left ventricular function; corneal and dermal wound healing, where topical formulations have entered clinical trials; and central nervous system repair, with reports of effects on neurogenesis in stroke models.
The compound is supplied here for laboratory research use only and is not intended for human consumption. Researchers should be aware that the synthetic TB-500 fragment and full-length recombinant Tbeta4 are distinct molecular entities, and study designs should specify which preparation is used.
Mechanism
Thymosin beta-4 binds G-actin with high affinity through its central LKKTETQ motif and surrounding residues, sequestering monomeric actin and regulating the dynamic equilibrium between monomeric and filamentous actin. This sequestration activity influences cell motility, cytoskeletal remodeling, and migration responses required for wound repair.
Beyond actin binding, Tbeta4 has been shown to exert additional bioactivities including upregulation of vascular endothelial growth factor (VEGF), induction of laminin-5, and modulation of inflammatory cytokine networks. In endothelial cells, the protein promotes migration and tube formation in Matrigel assays. In cardiomyocyte and epicardial preparations, Tbeta4 has been observed to activate the epicardium and promote progenitor-like phenotypes through a pathway involving PINCH and integrin-linked kinase. The shorter TB-500 fragment retains actin-binding activity and is reported to engage some but not all of the downstream signaling effects of the full-length protein.
Research history
Thymosin beta-4 was isolated from bovine thymus by Allan Goldstein and colleagues in the early 1980s as part of a broader characterization of thymic peptides. The actin-sequestering function was identified by Safer, Nachmias, and others in the early 1990s, establishing the protein as a fundamental regulator of cytoskeletal dynamics.
Research interest expanded substantially in the 2000s following reports from the Srivastava and Riley laboratories that Tbeta4 administration in murine myocardial infarction models preserved cardiac function and activated epicardial progenitors. Clinical research programs explored topical Tbeta4 formulations for dry eye disease and pressure ulcer healing, with several phase 2 and phase 3 trials reported.
The synthetic TB-500 designation entered the research-chemical and equine veterinary markets in the late 2000s, with limited published characterization. Academic research on thymosin beta-4 has continued through 2025 with investigations in stroke recovery, corneal repair, cardiac regeneration, and dermal wound healing models. Reviews have emphasized the need for careful distinction between full-length recombinant protein and synthetic fragments when interpreting cross-study results.
References
- Goldstein AL, et al. 2012. Thymosin beta4: a multi-functional regenerative peptide. Expert Opin Biol Ther. PMID: 22439792
- Bock-Marquette I, et al. 2004. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. PMID: 15525990
- Smart N, et al. 2007. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. PMID: 17572662
- Sosne G, et al. 2010. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo. Exp Eye Res. PMID: 19819239
- Crockford D, et al. 2010. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. PMID: 20536942
- Goldstein AL, Hannappel E, Kleinman HK. 2005. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. PMID: 16002336
Do you have any questions about TB-500?
Pick a path. The research assistant has the full literature context loaded.
Information presented in third-person scientific context. Research use only. Not medical advice; not for human consumption.